title: Pros and cons for the development of new antiepileptic drugs.
abstract: There continues to be an escalation in the number of new antiepileptic drugs, with many recently marketed drugs and many more entering clinical trials. This growth begs the question as to whether we need additional antiepileptic drugs. We consider the answer to this question from the medical perspective and also from the viewpoint of the pharmaceutical industry, health providers and from a more global, international perspective. There is undoubtedly a medical need for new antiepileptic drugs, and despite growing competition, the antiepileptic drug market remains profitable. However, in health services with limited resources, it is important that this expense is not offset by failure to research more appropriate use of existing antiepileptic drugs that may have a greater impact on healthcare. This is especially true for developing countries where resources would be much better spent on prevention and closing the treatment gap (the difference between those who can be treated and those who are treated).
authors: Department of Pharmaceutics and David R. Bloom Centre for Pharmacy, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel.
authors: Meir
authors: M
authors: Bialer
authors: Matthew C
authors: MC
authors: Walker
authors: Josemir W
authors: JW
authors: Sander
mesh_terms: D000927:Anticonvulsants / Q000191:economics / Q000494:pharmacology* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004345:Drug Industry / Q000191:economics / Q000639:trends; D014943:Global Health; D006282:Health Personnel; D006801:Humans; D012640:Seizures / Q000188:drug therapy*; D013678:Technology, Pharmaceutical
chemical_list: D000927:Anticonvulsants